Madrigal Pharmaceuticals, Inc. (MDGL)

NASDAQ: MDGL · Real-Time Price · USD

497.27

-18.69 (-3.62%)

At close: May 29, 2026, 4:00 PM EDT

500.00

+2.73 (0.55%)

After-hours: May 29, 2026, 6:40 PM EDT

Madrigal Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	1,132	958.4	180.13	-	-	-
Revenue Growth (YoY)	256.82%	432.05%	-	-	-	-
Cost of Revenue	78.48	56.15	6.23	-	-	-
Gross Profit	1,054	902.26	173.9	-	-	-
Selling, General & Admin	914.47	813.83	435.06	108.15	48.13	37.32
Research & Development	453.05	388.53	236.72	272.35	245.44	205.16
Total Operating Expenses	1,368	1,202	671.78	380.5	293.57	242.48
Operating Income	-313.51	-300.1	-497.88	-380.5	-293.57	-242.48
Interest Income	36.24	37.36	46.65	19.58	2.19	0.36
Interest Expense	-26.83	-22.31	-14.67	-12.71	-3.96	-
Other Non-Operating Income (Expense)	-5.33	-3.24	-	-	-	0.27
Total Non-Operating Income (Expense)	4.07	11.81	31.98	6.87	-1.78	0.64
Pretax Income	-309.44	-288.28	-465.89	-373.63	-295.35	-241.85
Net Income	-309.44	-288.28	-465.89	-373.63	-295.35	-241.85
Net Income to Common	-309.44	-288.28	-465.89	-373.63	-295.35	-241.85
Shares Outstanding (Basic)	24	22	21	19	17	17
Shares Outstanding (Diluted)	24	22	21	19	17	17
Shares Change (YoY)	3.64%	5.46%	13.83%	9.05%	3.64%	7.05%
EPS (Basic)	-12.80	-12.85	-21.90	-19.99	-17.23	-14.63
EPS (Diluted)	-12.80	-12.85	-21.90	-19.99	-17.23	-14.63
Shares Outstanding	25.41	25.21	22	19.88	18.1	17.1
Free Cash Flow	-272.41	-190.02	-457.03	-325.71	-225.07	-184.13
Free Cash Flow Per Share	-11.29	-8.47	-21.48	-17.43	-13.13	-11.14
Gross Margin	93.07%	94.14%	96.54%	-	-	-
Operating Margin	-27.68%	-31.31%	-276.39%	-	-	-
Profit Margin	-27.32%	-30.08%	-258.64%	-	-	-
FCF Margin	-24.05%	-19.83%	-253.72%	-	-	-
EBITDA	-312	-298.59	-496.78	-379.97	-293.1	-242.08
EBITDA Margin	-27.55%	-31.16%	-275.78%	-	-	-
EBIT	-313.51	-300.1	-497.88	-380.5	-293.57	-242.48
EBIT Margin	-27.68%	-31.31%	-276.39%	-	-	-

SEC Filings: 10-K · 10-Q